FoxP3 demethylation is increased in human colorectal cancer and rat cholangiocarcinoma tissue

Clinical Biochemistry

Volumn 47, Issue 3, 2014, Pages 201-205

  Schultze, Frank Christian ^a   Andag, Reiner ^a   Alwahsh, Salamah Mohammad ^a   Toncheva, Draga ^b   Maslyankov, Svilen ^c   Yaramov, Nikolay ^c   von Ahsen, Nicolas ^a   Brandhorst, Gunnar ^a   Walson, Philip D ^a   Oellerich, Michael ^a   Petrova, Darinka Todorova ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^c Aleksandrovska Hospital   (Bulgaria)

Author keywords

CD3; Colorectal cancer (CRC); FoxP3; Intrahepatic cholangiocarcinoma (ICC); Promoter demethylation

Indexed keywords

CD3 ANTIGEN; GENOMIC DNA; THIOACETAMIDE; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL; CANCER PATIENT; CANCER TISSUE; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DEMETHYLATION; DNA CONTENT; HUMAN; HUMAN TISSUE; MALE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; TUMOR IMMUNITY;

CD3; COLORECTAL CANCER (CRC); FOXP3; INTRAHEPATIC CHOLANGIOCARCINOMA (ICC); PROMOTER DEMETHYLATION;

ADULT; AGED; ANIMALS; ANTIGENS, CD3; CHOLANGIOCARCINOMA; COLORECTAL NEOPLASMS; DNA METHYLATION; DNA, NEOPLASM; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROMOTER REGIONS, GENETIC; RATS; T-LYMPHOCYTES, REGULATORY; TUMOR MARKERS, BIOLOGICAL;

EID: 84893803900     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2013.11.013     Document Type: Article

References (23)

1. Zheng Y., Rudensky A.Y. Foxp3 in control of the regulatory T cell lineage. Nat Immunol 2007, 8:457-462.
2. +) T cells as target for immune therapy of cervical intraepithelial neoplasia and cervical cancer. Cancer Sci 2009, 100:1112-1117.
3. Shalev I., Schmelzle M., Robson S.C., Levy G. Making sense of regulatory T cell suppressive function. Semin Immunol 2011, 23:282-292.
4. Hasita H., Komohara Y., Okabe H., Masuda T., Ohnishi K., Lei X.F., et al. Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. Cancer Sci 2010, 101:1913-1919.
5. Gu F.M., Gao Q., Shi G.M., Zhang X., Wang J., Jiang J.H., et al. Intratumoral IL-17(+) cells and neutrophils show strong prognostic significance in intrahepatic cholangiocarcinoma. Ann Surg Oncol 2012, 19:2506-2514.
6. + regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 2007, 13:902-911.
7. + regulatory T cells in human colorectal cancer. J Transl Med 2006, 4:52.
8. Minoo P., Zlobec I., Peterson M., Terracciano L., Lugli A. Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles. Int J Oncol 2010, 37:707-718.
9. Nagorsen D., Voigt S., Berg E., Stein H., Thiel E., Loddenkemper C. Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival. J Transl Med 2007, 5:62.
10. Ling K.L., Pratap S.E., Bates G.J., Singh B., Mortensen N.J., George B.D., et al. Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immun 2007, 7:7.
11. + regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS One 2006, 1:e129.
12. Wieczorek G., Asemissen A., Model F., Turbachova I., Floess S., Liebenberg V., et al. Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res 2009, 69:599-608.
13. Petrova D.T., Yaramov N., Toshev S., Nedeva P., Maslyankov S., von Ahsen N., et al. Genotyping of CYP3A5 polymorphisms among Bulgarian patients with sporadic colorectal cancer and controls. Onkologie 2007, 30:559-563.
14. Petrova D.T., Nedeva P., Maslyankov S., Toshev S., Yaramov N., Atanasova S., et al. No association between MDR1 (ABCB1) 2677G>T and 3435C>T polymorphism and sporadic colorectal cancer among Bulgarian patients. J Cancer Res Clin Oncol 2008, 134:317-322.
15. Wójcik M., Ramadori P., Blaschke M., Sultan S., Khan S., Malik I.A., et al. Immunodetection of cyclooxygenase-2 (COX-2) is restricted to tissue macrophages in normal rat liver and to recruited mononuclear phagocytes in liver injury and cholangiocarcinoma. Histochem Cell Biol 2012, 137:217-233.
16. Sehouli J., Loddenkemper C., Cornu T., Schwachula T., Hoffmüller U., Grützkau A., et al. Epigenetic quantification of tumor-infiltrating T-lymphocytes. Epigenetics 2011, 6:236-246.
17. Zlobec I., Lugli A. Invasive front of colorectal cancer: dynamic interface of pro-/anti-tumor factors. World J Gastroenterol 2009, 15:5898-5906.
18. Nosho K., Baba Y., Tanaka N., Shima K., Hayashi M., Meyerhardt J.A., et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 2010, 222:350-366.
19. Sibulesky L., Nguyen J., Patel T. Preneoplastic conditions underlying bile duct cancer. Langenbecks Arch Surg 2012, 397:861-867.
20. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pagès C., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
21. +) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology 2009, 137:1270-1279.
22. + T lymphocyte density in human colon carcinomas. PLoS One 2012, 7:e42274.
23. Guan Y., Yu S., Zhao Z., Ciric B., Zhang G.X., Rostami A. Antigen presenting cells treated in vitro by macrophage colony-stimulating factor and autoantigen protect mice from autoimmunity. J Neuroimmunol 2007, 192:68-78.